Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?

American Journal of Cardiology

Volumn 86, Issue 8 SUPPL. 2, 2000, Pages 35-42

  Waters, David D ^a   Azar, Rabih R ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; STATIN;

ATHEROGENESIS; CHOLESTEROL METABOLISM; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; SURVIVAL; THROMBOCYTE AGGREGATION; THROMBOGENICITY;

EID: 0034687360     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01226-1     Document Type: Article

References (66)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
6. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S)
7. Cholesterol lowering: Should it continue to be the last thing we do?
8. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
9. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
10. Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris
11. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
12. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
13. Aspirin, heparin, or both to treat unstable angina
14. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease
15. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
16. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
17. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
18. Low-molecular-weight heparins for unstable angina: A better mousetrap?
19. A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
20. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B study
21. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
22. Platelet IIb-IIIa blockers
23. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
24. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
25. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial, SYMPHONY Steering Committee
26. Close relation of endothelial function in the human coronary and peripheral circulations
27. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines
28. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
29. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
30. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
31. The effect of cholesterol-lowering and antioxidant therapy on endothelial-dependent coronary vasomotion
32. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
33. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
34. Vasoreactivity of the culprit lesion in unstable angina
35. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial
36. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
37. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle
38. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery
39. LPC in oxidized LDL elicits vasoconstriction and inhibits endothelium-dependent relaxation
40. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries
41. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta
42. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta
43. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
44. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
45. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease
46. Platelet function in hyperlipoproteinemia
47. 2 by platelets in vitro
48. Increased thromboxane biosynthesis in type IIa hypercholesterolemia
49. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium-111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene
50. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
51. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin
52. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
53. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
54. Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: Effect of simvastatin
55. + antiport in human platelets: A novel mechanism enhancing platelet activity in hypercholesterolemia
56. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men
57. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
58. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
59. Long-term effects of pravastatin on plasma concentration of C-reactive protein
60. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
61. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
62. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells
63. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
64. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions
65. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
66. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave myocardial infarction